171 related articles for article (PubMed ID: 37295057)
1. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study.
Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T
J Infect Public Health; 2023 Aug; 16(8):1249-1255. PubMed ID: 37295057
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
3. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baummannii in critically ill cancer patients: a retrospective cohort study.
Nazer LH; Rihani S; Hawari FI; Le J
Infect Dis (Lond); 2015; 47(11):755-60. PubMed ID: 26050703
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
5. Short-Course Versus Long-Course Colistin for Treatment of Carbapenem-Resistant
Katip W; Uitrakul S; Oberdorfer P
Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33922151
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant
Katip W; Uitrakul S; Oberdorfer P
Antibiotics (Basel); 2020 Sep; 9(10):. PubMed ID: 32998187
[TBL] [Abstract][Full Text] [Related]
7. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
[TBL] [Abstract][Full Text] [Related]
8. Clinical Efficacy and Nephrotoxicity of Colistin Alone versus Colistin Plus Vancomycin in Critically Ill Patients Infected with Carbapenem-Resistant
Katip W; Oberdorfer P
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33530483
[No Abstract] [Full Text] [Related]
9. Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: A multicentre retrospective propensity score-matched study.
Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK;
Int J Antimicrob Agents; 2024 Jan; 63(1):107044. PubMed ID: 38040319
[TBL] [Abstract][Full Text] [Related]
10. Early Intravenous Colistin Therapy as a Favorable Prognostic Factor for 28-day Mortality in Patients with CRAB Bacteremia: a Multicenter Propensity Score-Matching Analysis.
Kim T; Park KH; Yu SN; Park SY; Park SY; Lee YM; Jeon MH; Choo EJ; Kim TH; Lee MS; Lee E
J Korean Med Sci; 2019 Oct; 34(39):e256. PubMed ID: 31602826
[TBL] [Abstract][Full Text] [Related]
11. The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter Baumannii-associated pneumonia in intensive care unit: a multicenter observational study.
Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK
Sci Rep; 2023 Jan; 13(1):140. PubMed ID: 36599842
[TBL] [Abstract][Full Text] [Related]
12. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
Amat T; Gutiérrez-Pizarraya A; Machuca I; Gracia-Ahufinger I; Pérez-Nadales E; Torre-Giménez Á; Garnacho-Montero J; Cisneros JM; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24(6):630-634. PubMed ID: 28970161
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study.
Feng JY; Peng CK; Sheu CC; Lin YC; Chan MC; Wang SH; Chen CM; Shen YC; Zheng ZR; Lin YT; Yang KY;
Clin Microbiol Infect; 2021 Oct; 27(10):1465-1473. PubMed ID: 33540113
[TBL] [Abstract][Full Text] [Related]
14. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea.
Seok H; Choi WS; Lee S; Moon C; Park DW; Song JY; Cheong HJ; Kim J; Kim JY; Park MN; Kim YR; Lee HJ; Kim B; Pai H; Jo YM; Kim JH; Sohn JW
J Glob Antimicrob Resist; 2021 Mar; 24():429-439. PubMed ID: 33571708
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
Falcone M; Tiseo G; Leonildi A; Della Sala L; Vecchione A; Barnini S; Farcomeni A; Menichetti F
Antimicrob Agents Chemother; 2022 May; 66(5):e0214221. PubMed ID: 35311522
[TBL] [Abstract][Full Text] [Related]
16. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
[TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant
Katip W; Uitrakul S; Oberdorfer P
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056926
[TBL] [Abstract][Full Text] [Related]
18. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
Batirel A; Balkan II; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1311-22. PubMed ID: 24532009
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for the first episode of
Mantzarlis K; Makris D; Zakynthinos E
J Med Microbiol; 2020 Jan; 69(1):35-40. PubMed ID: 31647404
[No Abstract] [Full Text] [Related]
20. Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study.
Chen CY; Yang KY; Peng CK; Sheu CC; Chan MC; Feng JY; Wang SH; Chen CM; Zheng ZR; Liang SJ; Lin YC;
Sci Rep; 2022 May; 12(1):7501. PubMed ID: 35525867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
